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doi:10.1016/j.jfma.2011.06.016Background/Purpose: Hereditary spastic paraplegias (HSPs) are clinically and genetically
heterogeneous neurodegenerative disorders. Defects in the SPG4 and SPG3A genes are the
two leading causes of HSPs with autosomal dominant inheritance (AD-HSPs). The purpose of
this study was to investigate the clinical features and associated genetic mutations in
Taiwanese families with AD-HSP.
Methods: Four kindreds with AD-HSP were recruited, and clinical data were collected from the
affected individuals. Genetic studies were conducted in the following order: sequence analysis
of the SPG4 gene (SPAST ) exons, multiplex ligation-dependent probe amplification to detect
genetic rearrangements in SPAST, and sequence analysis of the SPG3A gene exons.
Results: Four different SPAST mutations were detected, including a novel small deletion,
a missense mutation, and two gross deletions involving exon 17. Although all symptomatic
cases manifested as uncomplicated phenotypes, considerable intrakindred and inter-
kindred variations in terms of age at onset, rate of progression, and severity of disease were
observed.of Neurology, Neuroscience Research Center, Chang Gung Memorial Hospital, Linko Medical Center,
icine, Taoyuan, Taiwan.
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Taiwanese families with autosomal dominant hereditary spastic paraplegia 381Figure 1 Pedigrees of four fami
represent male subjects, and the di
symbols indicate affected individual
cases that were involved in the cl
phenotypes of the cases that wereConclusion: Mutation patterns and phenotypic expressivity are heterogeneous in Taiwanese
patients with SPG4-related HSP. Genetic rearrangements could be a significant cause of
SPG4-related HSP in the Taiwanese population. Assessment of the large deletions that could
present in SPAST is warranted when direct sequencing is uninformative.
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Hereditary spastic paraplegias (HSPs) are a heterogeneous
group of neurodegenerative disorders that are character-
ized by progressive spasticity and weakness of the lower
limbs.1 Genetically, all modes of inheritance, including
autosomal dominant, autosomal recessive, and X-linked,
have been characterized as HSPs. Autosomal dominant HSPs
(AD-HSPs) represent around 70% of cases of uncomplicated
HSPs (also referred to as “pure HSPs” when spastic para-
plegia is the sole manifestation).2 For all AD-HSP families,
mutations in SPG4 and SPG3A are the two most common
causes, accounting for around 40% and 10% of pedigrees,
respectively.
Several clinical and genetic studies on SPG3A- and
SPG4-related HSP have been reported in the Han Chinese
population.3e5 In the present study, we investigated the
clinical features and performed genetic analysis on the
SPG4 and SPG3A genes in Taiwanese AD-HSP patients. Tolies with hereditary spastic pa
amond represents the patient w
s with a detected mutation. The
inical and genetic studies are
not examined are defined accothe best of our knowledge, this is the first report on genetic
mutations in Taiwanese families with AD-HSP.Methods and materials
Four unrelated ethnic Han Taiwanese kindreds with AD-HSP
were included in this study (Fig. 1). The diagnosis of AD-HSP
is based on the following diagnostic criteria: (1) pure
spastic paraplegia; (2) spastic tetraparesis with earlier and
more severe effects to lower limbs; (3) spastic paraplegia
as an early and prominent sign of a degenerative disease
affecting the nervous system; (4) positive family history of
spastic gait disturbance with affected members in at least
two generations; and (5) exclusion of other causes that
could explain the presenting symptoms.2 Clinical informa-
tion and family histories were collected and neurological
examinations were performed by a neurologist according to
a standard protocol. The study protocol was approved byraplegia. The circles represent female subjects, the squares
hose gender was withheld for confidentiality reasons. The filled
hatched symbols denote asymptomatic mutation carriers. The
indicated with a cross bar above the individual symbol. The
rding to the information provided by other family members.
382 M.-Y. Lan et al.the Institutional Review Board of Chang Gung Memorial
Hospital (No. 99-2103B). Written informed consent was
obtained from all patients who participated in this study.
Mutation screenings were conducted in the following
order. First, we used polymerase chain reaction (PCR) and
direct sequencing to analyze the mutations caused by
nucleotide substitutions or small deletions or insertions into
any of the exons, including adjacent splice sites in the SPG4
gene, SPAST. If no mutations were detected, multiplex
ligation-dependent probe amplification (MLPA) was per-
formed to detect exonic deletions and duplications in
SPAST. For the remaining kindreds that did not demon-
strated any detected mutations in SPAST, sequence analysis
of the exons of the SPG3A gene, ATL1, was performed.
Genomic DNA was extracted from peripheral blood
leukocytes for genetic analysis. All exons and flanking
intronic regions of SPAST and ALT1 were amplified by PCR.
The amplified fragments were directly sequenced. S44L and
P45Q polymorphisms in SPAST were genotyped by direct
sequence analysis. MLPA was performed using the SALSA
MLPA kit (P165-B1 HSP/Spastin; MRC-Holland, Amsterdam,
Netherlands) according to the manufacturer’s instructions,
and data were analyzed as previously described.6 For each
sample, a normalized ratio of the relative peak area
between 0.8e1.2 was considered normal. Heterozygous
deletions were indicated by a ratio between 0.3e0.7.
mRNA analysis was performed to assess the extent of the
deletions and their probable effects on protein translation
when an exonic deletion was detected by MLPA. Total
mRNA was extracted from the blood leukocytes using Trizol
(Invitrogen, Carlsbad, CA, United States) and converted to
cDNA using the High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems, Foster City, CA, United States)
according to the manufacturer’s instructions. Primers were
designed for PCR amplification of the cDNA segments that
encompassed the putative deleted region. The amplified
fragments were then subjected to direct sequencing.Results
SPAST mutations were discovered in all four kindreds. In
family 1, a novel mutation consisting of a two-base deletion
in exon 16 (c.1714_1715 del AT) caused a shift in the open
reading frame and the premature termination of translation
(p.M572VfsX3). In family 3, we identified a point mutation in
exon 11 that lead to an amino acid substitution (c.1382T>C,
p.L461P), which has been previously reported (The Human
Gene Mutation Database website, http://www.hgmd.cf.ac.
uk/ac/index.php; Wolfenbuttel, German).7 The residue
leucine 461 is highly evolutionarily conserved according to
the public genome database (see HomoloGene on the
National Center for Biotechnology Information website,
http://www.ncbi.nlm.nih.gov/homologene; Bethesda, MD,
United States; and ClustalW2 on the European Bio-
informatics Institute website, http://www.ebi.ac.uk/
Tools/clustalw2/; Hinxton, Great Britain).8,9 These two
mutations were not detected in 100 unrelated ethnic Han
Taiwanese individuals who served as controls. All of the
individuals in the four kindreds carried the common alleles
(S and P) for the S44L and P45Q polymorphisms.In families 2 and 4, no mutation in SPAST was detected
by direct sequencing of the PCR products. In these two
families, MLPA showed aberrant profiles that suggested
a gross deletion involving SPAST exon 17. In family 2, the
signal of the exon 17A probe (its ligation site is located at
c.2031-2032, about 40 base pairs upstream of the stop
codon) was reduced, whereas the signal of the exon 17B
probe (its ligation site is located at c.3961-3962) was within
normal range, indicating a deletion that affected exon 17 at
the 5’-end (Fig. 2). cDNA analysis revealed the deletion of
the first 1090 bases of exon 17 at the mRNA level (Fig. 3).
According to the nucleotide sequence, it was predicted
that the aberrant mRNA transcript would cause the
replacement of the last 40 normal amino acids with 16
erroneous residues at the C-terminus of spastin
(M577DfsX16). In family 4, the signals of both the exon 17A
and exon 17 B probes were reduced (Fig. 2). However, the
effects of the deletion on translation could not be deter-
mined due to the failure to amplify the mutant transcript in
3’-untranslated region of SPAST by cDNA analysis. We
speculate that this deletion may involve the entire exon 17
and extend to outside of the SPAST gene. Because SPAST
mutations were discovered in all four families, further
analysis of the SPG3A gene was not performed.
The clinical characteristics of the affected members in
the four families are shown in Table 1. This study included
15 cases (female:male ratio of 8:6; the gender of one
patient was omitted for confidentiality reasons due to
young age; age range: 6e71 years old). All symptomatic
cases manifested as uncomplicated phenotypes and pre-
sented as motor dysfunction due to weakness or severe
spasticity of the lower limbs. A wide range of age at
symptom onset, from 1e50 years old, was noted. Neuro-
logical examinations of the cranial nerves and upper limbs
were normal except for accentuated jaw-jerk and tendon
reflex in some patients. There was no correlation between
duration of the disease and lower limb weakness, sphincter
dysfunction, distal sensory abnormalities, or ambulation
function. Considerable intrafamilial variation in terms of
age of onset, rate of progression, and severity of disease
were observed in families 2 and 3. Family 2 was remarkable
in terms of the progressively earlier disease onset in
successive generations, mimicking the phenomenon of
“anticipation.” Two members of family 3 (III-4 and III-7),
who were normal on neurological examination, also
carried the mutation found in the other symptomatic
familial members. Generally, there is no clear phenotypic
correlation with respect to the different patterns of
mutations.Discussion
SPG4-related dysfunction is the most common type of AD-
HSP and frequently manifests with uncomplicated pheno-
types. The product of the SPG4 gene (SPAST ), spastin, is
a member of the AAA (ATPase associated with diverse
cellular activities) family, which is characterized by
a common domain which mediates ATPase function called
the AAA cassette.10 Spastin can sever and disassemble
microtubules and regulate the functions in an ATPase-
dependent manner.11 Spastin also possesses an MIT
Figure 2 SPAST-specific multiple ligation-dependent probe amplification profiles of family 2 (upper panel) and family 4 (lower
panel). The values along the vertical axis represent the normalized ratios of the relative peak areas of the exons. A value between
0.8e1.2 is considered normal while a value between 0.3e0.7 indicates a heterozygous deletion of the exon. Exon-specific probes
with reduced signals (17A in family 2 and 17A and 17B in family 4) are highlighted by the black bars.
Taiwanese families with autosomal dominant hereditary spastic paraplegia 383(microtubule interacting and trafficking) domain in the N-
terminus, which may be involved in microtubule and
membrane interactions.12 Thus, SPAST mutations may
cause deleterious effects on the microtubule dynamicsFigure 3 Sequence analysis of the mutant transcript of
family 2. Deletion of the 5’-region of exon 17 is indicated.involved in cytoskeletal stability, axonal transport, and
intracellular trafficking; these effects may underlie the
axonal degeneration observed in HSP.
In the current study, SPAST mutations were found in all
four of the Taiwanese HSP kindreds by using a genetic
testing protocol to determine AD-HSP. These four muta-
tions, including a novel deletion, have not been reported in
ethnic Han Chinese persons.3,4 Furthermore, all of the
mutations affected the AAA cassette-encoding region of
SPAST. To date, more than 200 different mutations in SPAST
have been described (please see the HGMD website).
Interestingly, nonsense, splice site, and frameshift muta-
tions, which create premature termination codons, may
affect any exon while the majority of missense mutations
are located in the AAA cassette-encoding region. These
findings suggest the crucial role of the AAA cassette in the
functions of spastin. We also identified partial and entire
deletions of exon 17 in the SPAST gene of two kindreds. One
of the large deletions was predicted to cause a defect
equivalent to a frameshift with the premature termination
of translation by cDNA analysis. Genetic rearrangements,
including exonic deletions and duplications, have been
increasingly recognized as causes of SPG4-related HSP.6,13 It
Table 1 Clinical characteristics and identified mutations of hereditary spastic paraplegia patients.
Family Case Sex Age
(years)
Age at
onset
(years)
Muscle
powera
(P/D)
Extensor
plantar
reflex
Distal lower
limb vibratory
sensation loss
Sphincter
dysfunctionb
Ambulation
functionc
Detected
mutation
UE LE
1 I-2 F 52 12 5/5 4/5 þ þ þ 2 SPAST
c.1714_1715 del ATII-2 F 31 11 5/5 4/5 þ þ þ 2
2 I-2 F 61 42 5/5 5/5 þ þ þ 3 SPAST
Deletion of 5’- region
of exon 17
II-2 F 38 11 5/5 5/5 þ þ þ 2
III-1 NAd 6 1 5/5 5/5 þ þ þ 1 NAd
3 II-1 M 62 40 5/5 1/0 þ þ  4 SPAST
c.1382T>CII-2 M 58 53 5/5 5/5    2
II-3 M 52 42 5/5 4/5 þ  þ 3
III-4e M 30  5/5 5/5    1
III-5 F 27 24 5/5 5/5 þ   1
III-6 M 25 19 5/5 4/2 þ þ  3
III-7e F 25  5/5 5/5    1
4 III-1 F 71 50 5/5 4/3  þ þ 4 SPAST
Deletion of exon 17III-6 M 56 48 5/5 5/5    3
III-8 F 48 44 5/5 5/5    2
Abbreviations: D, distal; F, female; LE, lower extremities; M, male; P, proximal; UE, upper extremities.
a MRC grading.
b Urinary retention, frequency or incontinence.
c 1, able to run; 2, unable to run, walking independently; 3, walking with aid; 4, wheelchair bound.
d NA, not applicable (gender data omitted for confidentiality; mutation not tested due to ethical consideration).
e Asymptomatic mutation carrier.
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15e20% of AD-HSP families that test negative for SPAST
point mutations. Despite the small sample size of the
current study, our findings suggest that exonic deletion is
a significant cause of SPG4-related HSP in ethnic Han
Taiwanese individuals. Whether the genetic rearrangement
of SPAST also makes an important contribution to HSP in
Han Chinese individuals warrants further investigation.
Clinically, marked interkindred variability with respect
to age of onset, rate of progression, and disease severity
have been noted in SPG4-related HSP,14 similar to the
families described in this report. Apparent anticipation,
a special pattern of intrakindred variability occasionally
found in association with SPG4,15 was observed in our study
(family 2). We also found two asymptomatic mutation
carriers in family 3, suggesting the incomplete penetrance
of this mutation. However, long-term clinical follow-up
examinations are needed to confirm these conditions
because these two individuals are still young. Despite the
different types of SPG4 mutations that have been
described, no clear phenotype-genotype correlation can be
established. It is postulated that genetic modifiers may
account for the variability in SPG4 phenotypes. Missense
variants in the N-terminus of SPAST, including S44L and
P45Q, have been suggested to be rare polymorphisms that
may aggravate clinical features when they present in trans
to a classic SPAST mutation located in the AAA cassette-
encoding region.16 However, these polymorphisms, which
could be rare in ethnic Han Chinese individuals, were not
detected in our patients.In conclusion, our findings suggest that both mutation
patterns and phenotypic expressivity are heterogeneous in
Taiwanese patients with SPG4-related HSP. In light of the
increasing number of reported cases with genetic rear-
rangements in SPAST, assessment of large deletions using,
for instance, MLPA is warranted when direct sequencing is
negative or inconclusive.Acknowledgments
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